Haemonetics Corporation is a medical instruments & supplies business based in the US. Haemonetics Corporation shares (HAE) are listed on the NYSE and all prices are listed in US Dollars. Haemonetics Corporation employs 3,657 staff and has a trailing 12-month revenue of around $1.3 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $91.42 |
|---|---|
| 52-week range | $70.74 - $97.97 |
| 50-day moving average | $88.05 |
| 200-day moving average | $84.53 |
| Wall St. target price | $113.29 |
| PE ratio | 38.7467 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $2.29 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $91.42 from 2024-07-24
| 1 week (2024-07-18) | 5.58% |
|---|---|
| 1 month (2024-06-25) | 9.59% |
| 3 months (2024-04-25) | 4.29% |
| 6 months (2024-01-25) | 12.54% |
| 1 year (2023-07-25) | -0.39% |
|---|---|
| 2 years (2022-07-25) | 36.14% |
| 3 years (2021-07-23) | 54.79% |
| 5 years (2019-07-25) | 122.91 |
Valuing Haemonetics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Haemonetics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Haemonetics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Haemonetics Corporation shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Haemonetics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6326. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Haemonetics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Haemonetics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $295.5 million.
The EBITDA is a measure of a Haemonetics Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.3 billion |
|---|---|
| Operating margin TTM | 15.57% |
| Gross profit TTM | $530.8 million |
| Return on assets TTM | 6.26% |
| Return on equity TTM | 13.22% |
| Profit margin | 8.98% |
| Book value | $18.90 |
| Market Capitalization | $4.5 billion |
TTM: trailing 12 months
We're not expecting Haemonetics Corporation to pay a dividend over the next 12 months.
Haemonetics Corporation's shares were split on a 2:1 basis on 2 December 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Haemonetics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Haemonetics Corporation shares which in turn could have impacted Haemonetics Corporation's share price.
Over the last 12 months, Haemonetics Corporation's shares have ranged in value from as little as $70.74 up to $97.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Haemonetics Corporation's is 0.291. This would suggest that Haemonetics Corporation's shares are less volatile than average (for this exchange).
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.